Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel

Pharmacogenetics and Genomics

Volumn 22, Issue 7, 2012, Pages 498-507

  Njiaju, Uchenna O ^a   Gamazon, Eric R ^b   Gorsic, Lidija K ^a   Delaney, Shannon M ^a   Wheeler, Heather E ^a   Im, Hae Kyung ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Section of Genetic Medicine   (United States)

Author keywords

lymphoblastoid cell lines; paclitaxel; pharmacogenomics; solute carrier genes; transporters

Indexed keywords

PACLITAXEL;

APOPTOSIS; ARTICLE; CYTOTOXICITY; DRUG SENSITIVITY; GENE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOLUTE CARRIER 31A2 GENE; SOLUTE CARRIER 35A5 GENE; SOLUTE CARRIER 41A2 GENE; SOLUTE CARRIER 43A1 GENE;

EID: 84862760137     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328352f436     Document Type: Article

References (49)

1. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82:1247-1259. (Pubitemid 20239995)
2. Rowinsky EK, Wright M, Monsarrat B, Donehower RC. Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993. Ann Oncol 1994; 5 (Suppl 6):S7-S16.
3. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-983. (Pubitemid 46594124)
4. Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer 2008; 112 (Suppl 11):2577-2592.
5. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13:2575-2581.
6. Rodriguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics 2010; 11:621-623.
7. Zhang L, Brett CM, Giacomini KM. Role of organic cation transporters in drug absorption and elimination. Annu Rev Pharmacol Toxicol 1998; 38:431-460. (Pubitemid 28231502)
8. Zhang L, Huang SM, Lesko LJ. Transporter-mediated drug-drug interactions. Clin Pharmacol Ther 2011; 89:481-484.
9. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005; 4:815-818.
10. Gui C, Miao Y, Thompson L,Wahlgren B, Mock M, Stieger B, et al. Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 2008; 584:57-65.
11. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94:2031-2035. (Pubitemid 27113956)
12. Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004; 14:441-452. (Pubitemid 38971234)
13. Takano M, Otani Y, Tanda M, Kawami M, Nagai J, Yumoto R. Paclitaxelresistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2. Drug Metab Pharmacokinet 2009; 24:418-427.
14. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006; 12 (3 Pt 1): 854-859. (Pubitemid 43259868)
15. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007; 25:4528-4535. (Pubitemid 350035308)
16. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006; 42:2893-2896. (Pubitemid 44755257)
17. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci 2008; 97:2045-2048.
18. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007; 81:76-82. (Pubitemid 46050869)
19. Van de Steeg E, van Esch A, Wagenaar E, van der Kruijssen CM, van Tellingen O, Kenworthy KE, et al. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res 2011; 17:294-301.
20. Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 2012; 13:55-70.
21. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, et al. Platinum sensitivity-related germline polymorphism discovered via a cellbased approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 2011; 17:5490-5500.
22. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, et al. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 2011; 157:265-272.
23. Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, et al. Genetic variants in cytosolic 50-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther 2011; 339:9-23.
24. Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, Batzler AJ, et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2011; 17:5801-5811.
25. Peters EJ, Motsinger-Reif A, Havener TM, Everitt L, Hardison NE,Watson VG, et al. Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics 2011; 12:1407-1415.
26. Wen Y, Gorsic LK,Wheeler HE, Ziliak DM, Stephanie Huang R, Eileen Dolan M. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics 2011; 21:476-488.
27. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, et al. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet 2008; 82:631-640.
28. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci USA 2010; 107:9287-9292.
29. Gamazon ER, Duan S, Zhang W, Huang RS, Kistner EO, Dolan ME, et al. PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics 2010; 20:269-273.
30. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, et al. SCAN: SNP and copy number annotation. Bioinformatics 2010; 26:259-262.
31. Abecasis GR, Cardon LR, Cookson WO. A general test of association for quantitative traits in nuclear families. Am J Hum Genet 2000; 66: 279-292. (Pubitemid 30481489)
32. Wheeler HE, Gorsic LK, Welsh M, Stark AL, Gamazon ER, Cox NJ, et al. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One 2011; 6:e21920.
33. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010; 26:2190-2191.
34. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics 1998; 14:656-664. (Pubitemid 28504990)
35. Blair BG, Larson CA, Safaei R, Howell SB. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin Cancer Res 2009; 15:4312-4321.
36. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27:2604-2614.
37. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M,Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood 2005; 106:1133-1134; author reply 4.
38. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 2005; 57:573-578. (Pubitemid 40562396)
39. Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 2008; 7:3081-3091.
40. Gasnier B. The SLC32 transporter, a key protein for the synaptic release of inhibitory amino acids. Pflugers Arch 2004; 447:756-759. (Pubitemid 38241462)
41. Sahni J, Nelson B, Scharenberg AM. SLC41A2 encodes a plasmamembrane Mg2+ transporter. Biochem J 2007; 401:505-513. (Pubitemid 46170324)
42. Patel OV, Casey T, Dover H, Plaut K. Homeorhetic adaptation to lactation: comparative transcriptome analysis of mammary, liver, and adipose tissue during the transition from pregnancy to lactation in rats. Funct Integr Genomics 2011; 11:193-202.
43. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010; 62:1-96.
44. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009; 15:4750-4758.
45. Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 2010; 24:1243-1245.
46. Wu W, Dnyanmote AV, Nigam SK. Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis. Mol Pharmacol 2011; 79:795-805.
47. Vaughan KT. Microtubule plus ends, motors, and traffic of Golgi membranes. Biochim Biophys Acta 2005; 1744:316-324. (Pubitemid 40848250)
48. Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27:17-24. (Pubitemid 43063120)
49. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, et al. Pharmacogenomic discovery using cell-based models. Pharmacol Rev 2009; 61:413-429.